We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alimera Sciences Inc | NASDAQ:ALIM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 5.44% | 3.49 | 3.33 | 4.30 | 3.50 | 3.28 | 3.28 | 17,332 | 01:00:00 |
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on Thursday, March 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, March 2, 2017, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Fourth Quarter 2016 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 investorrelations@cg.capital
1 Year Alimera Sciences Chart |
1 Month Alimera Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions